Asymmetric Csp3 – Csp3 Suzuki−Miyaura Coupling Employing 1,1-Bisboryl Alkanes

Project Information

BISBORONDYKAT

Grant agreement ID: 890680

DOI

10.3030/890680

Project closed

EC signature date 5 March 2020

Start date 3 August 2020

End date 2 August 2022

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 212 933,76

EU contribution

€ 212 933,76

Coordinated by

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom

Periodic Reporting for period 1 - BISBORONDYKAT (Asymmetric Csp3 – Csp3 Suzuki−Miyaura Coupling Employing 1,1-Bisboryl Alkanes)

Reporting period: 2020-08-03 to 2022-08-02

Summary of the context and overall objectives of the project

The proposal was aimed to develop new C-C bond forming asymmetric reactions for the synthesis of chemical building blocks. Specifically, we intended to develop new Rh catalysed reactions using commercially available reagents that would provide access to highly versatile enantioenriched products. These methodologies provide access to pharmaceutically relevant molecules and drug candidates that would provide major advancement in the field of synthesis, medicinal and material chemistry.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The aim of the project was to develop a Csp3 – Csp3 Suzuki-Miyaura coupling employing 1,1’-bisboryl alkanes with racemic allyl halides in asymmetric SMC reactions. We successfully achieved the desired transformation, however, the method had was not broadly applicable. Consequently, we turned
our attention exploring other asymmetric Suzuki-Miyaura coupling reactions.

We discovered a new asymmetric synthetic route towards carbocyclic C-nucleosides, an underexplored class of nucleoside analogues. The methodology featured addition of challenging heterocyclic boronic acids featuring multiple heteroatoms. The addition of nucleobase type boronic acid provides a great progression in SMC coupling reactions. The synthetic route provides access to a chemical space which was previously almost inaccessible. Biological activities of these small molecule are currently under studies and will be reported in due course.

We also realized enantioselective synthesis of dihydropyridines, providing quick access to known drug candidates such as Isoanabasine, Preclamol, Niraparib and PPAR agonists. The method features rhodium catalysed carbometallation in relatively unactivated/strained alkene providing a significant advancement in the field of asymmetric SMC coupling reactions.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Even though we were unable to achieve a general Csp3 – Csp3 Suzuki-Miyaura coupling employ 1,1’-bisboryl alkanes with racemic allyl halides. We were able to develop multiple methodologies that we anticipate will be widely adopted by synthetic and medicinal chemists.

We try to develop chemistry relevant to current socio-economical needs, for example, our work on the synthesis of carbocyclic C-nucleosides as potent antiviral agent against Cov-SARS-2 was designed and develop during COVID-19 pandemic.

Summary.jpg